Anaphylaxis to Bovine Serum Albumin Tissue Adhesive in a Non–Meat-Allergic Patient

Hilger C\textsuperscript{1}, Clark E\textsuperscript{2}, Swiontek K\textsuperscript{1}, Chiriac AM\textsuperscript{1,4}, Caimmi DP\textsuperscript{3,4}, Demoly P\textsuperscript{3,4,5}, Bourrain JL\textsuperscript{2,3}

\textsuperscript{1}Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg
\textsuperscript{2}Department of Dermatology, CHU Montpellier, University of Montpellier I, Montpellier, France
\textsuperscript{3}Department of Pulmonology, Division of Allergy, Hôpital Arnaud de Villeneuve, University, Hospital of Montpellier, Montpellier, France
\textsuperscript{4}Sorbonne Université, INSERM UMR-S 1136, IPLESP, Equipe EPAR, Paris, France
\textsuperscript{5}WHO Collaborating Centre on Scientific Classification Support, Montpellier, France

doi: 10.18176/jiaci.0522


BioGlue (Cryolife) is a surgical adhesive that has been used since 1998 as an adjunct to standard methods of achieving hemostasis in adult patients during open surgical repair of large vessels. The adhesive is therefore commonly used as surgical sealant in thoracic surgery [1]. It is composed of purified bovine serum albumin (BSA) and glutaraldehyde, which are dispensed by means of a controlled delivery system. Upon mixing, the components polymerize into a flexible mechanical seal. The contraindications are limited (sensitivity to materials of bovine origin, intravascular use, cerebrovascular repair). Since its introduction, application of BioGlue has been expanded notably to include repair of traumatic liver laceration [2].

A 67-year-old atopic man was admitted to hospital for treatment of an aortic aneurysm. A Bentall procedure was performed using BioGlue. The patient experienced anaphylactic shock with bronchospasm and hypotension shortly after application and was treated with crystalloids, norepinephrine, epinephrine, and salbutamol. A blood sample taken during the event showed elevated serum tryptase (18.5 µg/L). The patient was referred to our allergology department for evaluation. He had a history of allergic rhinitis to cat dander, but no food allergies. The results of skin prick tests with cat, dog, hamster, guinea pig, and rabbit dander were positive. Specific Ig\text{E} (sIg\text{E}) was positive for Fel d 1 (21.6 kU\text{L}/L), Fel d 2 (3.7 kU\text{L}/L), and Fel d 4 (10.7 kU\text{L}/L) (ImmunoCAP, Thermo Fisher Scientific), but negative for Bos d 6. Skin prick tests were performed using both components of BioGlue, ie, native BSA and glutaraldehyde. The test was positive for BSA (5 mm) and negative for glutaraldehyde and the mixture of both.
In order to further elucidate the target of the patient’s IgE antibodies, we performed immunoblot inhibition assays on the BSA component of BioGlue and commercial BSA (Sigma-Aldrich). Proteins were separated by Coomassie-stained SDS-PAGE gel or immunoblotted as reported elsewhere [3] (Figure, A). IgE-reactivity was directed mostly toward high (>100 kDa) and low (35-40 kDa) molecular weight components in BioGlue and BSA samples. Reactivity was completely abolished by inhibition with BSA (100 µg/mL), thus confirming that all reactivity was directed toward the BSA component of BioGlue. In order to further understand the discrepancy between a positive immunoblot to BSA and a negative IgE test by ImmunoCAP, we assayed IgE binding to BSA in both the native and the denatured form (Figure, B). BSA was denatured using 1% SDS and 0.35 M β-mercaptoethanol and spotted onto a nitrocellulose membrane. IgE-reactivity to denatured cat serum albumin, the BSA component of BioGlue, and BSA is much stronger than that to native albumin, suggesting that IgE binding is predominantly directed against nonconformational epitopes, thus explaining the negative ImmunoCAP result with Bos d 6. A similar case of anaphylactic shock to BioGlue was reported in a patient who presented with pork-cat syndrome, although the test results for Bos d 6 were negative [4]. The patient in the present case did not report any symptoms upon ingestion of meat but has owned a cat for several years and has a history of allergic rhinitis in the presence of cats. We hypothesize that cross-reactive Fel d 2 epitopes in BSA would be exposed briefly to IgE antibodies during denaturation when mixing the 2 components, ie, BSA and glutaraldehyde. Solidification of the mixture and strong protein cross-linking would then preclude any further IgE binding and lead to an asymptomatic outcome. The severity of the reaction is probably due to the high concentration of BSA used in the product. A recent report on anaphylaxis to intravenous human serum albumin supports the idea that treated albumin could present structural changes capable of inducing sensitization and subsequent allergic responses upon administration. The patient was tolerant to human blood and plasma derivatives and did not present slgE to animal serum albumins [5].

The present case shows that patients with slgE to Fel d 2, even at low levels, may have a high risk of perioperative anaphylaxis upon using BioGlue as tissue adhesive. Cat-allergic patients should be screened for slgE to Fel d 2 before undergoing thoracic surgery. Up to 14%-23% of cat-allergic patients have been reported to be sensitized to Fel d 2, and about 1%-3% are likely to present pork-cat syndrome [6]. Despite the fact that surgical sealants composed of purified BSA are widely used, this is only the second case reported in the literature. In addition to slgE against Fel d 2, other, as yet unidentified cofactors might lead to the severe reactions described in the present case and reported by Dewachter et al [4]. The risk-benefit balance should be carefully assessed for each patient and alternative sealants considered.

Figure. IgE reactivity to bovine serum albumin (BSA). A, The BSA component of BioGlue (BioGlue) and a commercial BSA preparation were separated in Coomassie blue–stained SDS-PAGE gel (left) and immunoblotted with the patient’s serum (right). Cold water fish gelatin (2%) (Sigma) was used as blocking buffer. IgE reactivity to BioGlue and BSA was completely inhibited by addition of BSA. P indicates patient serum; N, negative control. B, Cat serum albumin (CSA), BioGlue and BSA were spotted onto nitrocellulose under denaturing or native conditions (10 µg/spot) and immunoblotted. IgE reactivity was markedly enhanced under denaturing conditions.
Metronidazole Hypersensitivity in a Patient With Angioedema and Widespread Rash
Aruanno A*, Parrinello G*, Buonomo A, Rizzi A, Nucera E
Allergy Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
*Both authors contributed equally to this work.

Metronidazole is a 5-nitroimidazole compound that was introduced in 1959 to treat Trichomonas vaginalis infections. It shares a high structural similarity with its derivatives (tinidazole, secnidazole, and ornidazole) and is used to treat parasitic infections, alone or in combination with other antibiotics. The drug is usually well tolerated, but may occasionally cause adverse effects (gastrointestinal symptoms, hematological alterations, central nervous system disorders, and, rarely, drug rashes) [1,2].

We can also find metronidazole in face creams and cosmetics. Sensitization may occur after their topical application.

We report a case of labial angioedema and widespread erythematous rash in a patient with type IV allergy to metronidazole.

A 45-year-old nonatopic man developed labial angioedema and widespread itchy erythematous maculopapular rash some 10 hours after the third dose of oral metronidazole prescribed for gastrointestinal dysbiosis. Symptoms disappeared within a few hours of administration of intravenous chlorphenamine and methylprednisolone. At the time of the event, the patient's blood count was normal, with no eosinophilia or lymphocytosis; there was no organ involvement, inflammatory markers were normal, and the patient was afebrile. After the event, he avoided the use of metronidazole in any form.

Three years later, the patient was admitted to the Allergy Department of Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy for an allergological work-up, which included skin prick tests (SPTs) and patch tests with metronidazole, as reported elsewhere [1,2]. The SPTs were carried out with metronidazole on the volar area of the forearm at 125 mg/mL in the form of powered tablets dissolved in saline. Histamine (10 mg/mL) was used as a positive control and saline (0.9%) as a negative control. Patch tests were applied on the interscapular region and carried out with metronidazole in the form of powdered tablets dissolved in petrolatum at concentrations of 0.5%, 5%, and 10% and with the undiluted solution. We also performed both tests in 10 healthy controls.

The SPT result was negative, while the patch tests indicated a positive reaction after 72 hours, with an erythematous...